BASILICA-A: A study into why anaplastic large cell lymphoma sometimes occurs after breast implants

This study is looking at why the rare type of lymphoma called anaplastic large cell lymphoma (ALCL) happens after a breast implant in a small number of women. 

You can share the following CRUK.org Identifier with your medical team so they can find out more about the trial: CRUK17642

Trial aim and background  

A very small number of women with breast implants will develop a rare form of lymphoma called anaplastic large cell lymphoma. This study does not involve any treatment but aims to try to understand the reasons why this happens. 

Women with breast implant associated ALCL usually undergo surgery to remove the lymphoma and the breast implant. In this study they will also have blood tests at these following times:

  • Before starting and after finishing chemotherapy (if this is required)
  • Before surgery
  • 4 weeks after surgery
  • 1 year after surgery

The research team will then use some of the tissue removed during surgery as well as the blood tests to study ALCL further and to find:

  • Whether there are changes in the number of white blood cells
  • Small pieces of circulating gene information (ctDNA)
  • The level of antibodies
  • Changes to proteins, cells and DNA

Samples will also be taken from women having breast implants for the first time for a comparison.

Who can enter

People aged 17 and over who have ALCL related to a breast implant and are being treated at the Royal Marsden Hospital may be eligible for this trial.  

Locations

Recruitment is taking place in the following UK locations:

  • Sutton
  • London

Further information 

More information about this trial can be found at https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-why-a-rare-type-of-lymphoma-happens-after-having-breast-implants-basilica-a

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.